Genmab — Maj 2021
-
Med HALO?
-
Er subq ikke blot en forkortelse af subcutan?
-
Jo
-
Hmm - her er vist et område, vi kan tage op ved næste PI Chat med GEN
-
HALO er ikke med indover epco!
-
Kesimplta bliver også beskrevet som SubQ- og dem har halo vist ikke været inde over
-
..men jeg har ikke hørt om revenue cuts/royalties på hverken kesimpta eller epco
-
Det er tidligere blevet beskrevet, at HALO ikke behøves p.g.a. de små doseringer...
-
Det giver mening
-
that is why i hoped for the same with hexacd38, and Jan's answer was in the same direction: 'At this moment we are testing different doses of HexaBody Cd38 in mm patients. If the
efficacy follows the very promising preclinical profile it may indeed be possible to use
3 / 6
Q&A GENMAB
17TH OF MAY 2021
WITH JAN VAN DE WINKEL
far lower doses than with daratumumab. If that follows from the clinical testing, we
may be able to dose subcutaneously without hyaluronidase in deed.' -
Nice! Thx EL
-
Gilead’s Magrolimab is an Investigational Anti-CD47 Monoclonal Antibody- in new trial with a.o. Dara here for MM
https://clinicaltrials.gov/ct2/show/NCT04892446 (just after Sukkeralf asked Jan about the Blink cooperation...)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind